title: Recommendations for using TNFα antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health.
abstract: The use of TNFα antagonists must follow specific guidelines to ensure optimal effectiveness and safety. The French Society for Rheumatology (SFR) and Task Force on Inflammatory Joint Diseases (CRI), in partnership with several French learned societies, asked the French National Authority for Health (HAS) to develop and endorse good practice guidelines for the prescription and monitoring of TNFα antagonist therapy by physicians belonging to various specialties. These guidelines were developed, then, validated by two multidisciplinary panels of experts based on an exhaustive review of the recent literature and in compliance with the methodological rules set forth by the HAS. They pertain to the initial prescription of TNFα antagonists and to a variety of clinical situations that can arise during the follow-up of patients receiving TNFα antagonists (infections, malignancies, pregnancy, vaccination, paradoxical adverse events, surgery, use in older patients, and vasculitides).
authors.affiliation: Service de Rhumatologie, CHU d'Amiens et EA 4666, Faculté de Médecine, Université Picardie-Jules-Verne, Amiens, France. Electronic address: goeb.vincent@chu-amiens.fr.
authors.forename: Vincent
authors.initials: V
authors.lastname: Goëb
authors.forename: Marc
authors.initials: M
authors.lastname: Ardizzone
authors.forename: Laurent
authors.initials: L
authors.lastname: Arnaud
authors.forename: Jérôme
authors.initials: J
authors.lastname: Avouac
authors.forename: Athan
authors.initials: A
authors.lastname: Baillet
authors.forename: Alexandre
authors.initials: A
authors.lastname: Belot
authors.forename: Béatrice
authors.initials: B
authors.lastname: Bouvard
authors.forename: Pascal
authors.initials: P
authors.lastname: Coquerelle
authors.forename: Sabrina
authors.initials: S
authors.lastname: Dadoun
authors.forename: Alain
authors.initials: A
authors.lastname: Diguet
authors.forename: David
authors.initials: D
authors.lastname: Launay
authors.forename: Danielle
authors.initials: D
authors.lastname: Lebouc
authors.forename: Pierre
authors.initials: P
authors.lastname: Loulergue
authors.forename: Sophie
authors.initials: S
authors.lastname: Mahy
authors.forename: Pascal
authors.initials: P
authors.lastname: Mestat
authors.forename: Gaël
authors.initials: G
authors.lastname: Mouterde
authors.forename: Benjamin
authors.initials: B
authors.lastname: Terrier
authors.forename: Coralie
authors.initials: C
authors.lastname: Varoquier
authors.forename: Mathieu
authors.initials: M
authors.lastname: Verdet
authors.forename: Xavier
authors.initials: X
authors.lastname: Puéchal
authors.forename: Jean
authors.initials: J
authors.lastname: Sibilia
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha
keywords: Adalimumab; Cancer; Certolizumab; Etanercept; French National Authority for Health (HAS); Golimumab; Infection; Infliximab; Older patients; Paradoxical adverse events; Pregnancy; Recommendations; Surgery; TNFα antagonist; Vaccination; Vasculitis